Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 reven

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized ba

Nasdaq 100 hits a record as Brazil's EWZ jumps 13% on Bolsonaro's election upset; ISM servic

Insmed Inc. (NASDAQ:INSM) shares are trading lower by almost 7% on Monday as traders digest a CFO tr

Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.

Insmed (NASDAQ:INSM) reported second-quarter financial results on Thursday. The transcript from the

Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and mome

— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership

Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the pri

Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized b

The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medicat

INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly di

Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsup

Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliv

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full

Company-wide day of service brings together more than 1,350 employees to support over 50 organizatio

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price t

Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Tr

Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels. BRINSUPRI's

BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first

— New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibr

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first

Duquesne Family Office has beefed up its healthcare holdings.

The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2

— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosi

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the se

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDA

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree

Crude's rebound on Yemen strikes pulled U.S. equities off record highs Thursday, while SanDisk p

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Dow drops over 300 points, NASDAQ down 0.05% and S&P 500 down 0.19%. Keurig Dr Pepper reports st

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporti

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

Nebius Group N.V. (NASDAQ: NBIS) stock surged on Tuesday after confirming its upcoming addition to t

CoreWeave, Astera Labs, Nebius, Rocket Lab & Teradyne join the Nasdaq-100. Jim Cramer calls this

CRWV stock climbs 5% as CoreWeave gears up to join the Nasdaq-100. Get the latest price action, incl

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys

ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex

Weak earnings, soft guidance and analyst target cuts triggered sharp selloffs across healthcare, sof

U.S. stocks drifted near records Thursday as oil slipped on Iran-Hormuz peace hopes. Coinbase, Airbn

Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful